TRVI · Insider Trading
Trevi Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TRVI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Michael Thomas Heffernan | Director | MIXED | +100 | −$468.11K |
| 2026-06-04 | Edward T Mathers | Director | A | +35,000 deriv. | — |
| 2026-06-04 | Dominick Colangelo | Director | A | +35,000 deriv. | — |
| 2026-06-04 | David P Meeker | Director | A | +35,000 deriv. | — |
| 2026-06-04 | Michael Thomas Heffernan | Director | A | +35,000 deriv. | — |
| 2026-06-04 | Anne Vanlent | Director | A | +35,000 deriv. | — |
| 2026-02-20 | Thomas Sciascia | Chief Scientific Officer | A | +85,000 deriv. | — |
| 2026-02-20 | Christopher Galletta | See Remarks | A | +35,000 deriv. | — |
| 2026-02-20 | Jennifer L Good | President & CEO | A | +675,000 deriv. | — |
| 2026-02-20 | James V Cassella | Chief Development Officer | A | +215,000 deriv. | — |
| 2026-02-20 | Farrell Simon | Chief Commercial Officer | A | +160,000 deriv. | — |
| 2026-01-12 | David C Hastings | Chief Financial Officer | A | +375,000 deriv. | — |
| 2025-12-03 | Christopher Galletta | See Remarks | M | +4,225 | +$2.16K |
| 2025-06-13 | Michael Thomas Heffernan | Director | A | +45,000 deriv. | — |
| 2025-06-13 | Anne Vanlent | Director | A | +45,000 deriv. | — |
| 2025-06-13 | Edward T Mathers | Director | A | +45,000 deriv. | — |
| 2025-06-13 | David P Meeker | Director | A | +45,000 deriv. | — |
| 2025-06-13 | Dominick Colangelo | Director | A | +45,000 deriv. | — |
| 2025-06-03 | Jennifer L Good | President & CEO | A | +102,000 deriv. | — |
| 2025-06-03 | Lisa Delfini | Chief Financial Officer | A | +72,000 deriv. | — |
| 2025-06-03 | Christopher Galletta | See Remarks | A | +8,550 deriv. | — |
| 2025-06-03 | Farrell Simon | Chief Commercial Officer | A | +72,000 deriv. | — |
| 2025-06-03 | Thomas Sciascia | Chief Scientific Officer | A | +60,000 deriv. | — |
| 2025-03-26 | Thomas Sciascia | Chief Scientific Officer | MIXED | — | −$13.60K |
| 2025-03-25 | Jennifer L Good | President & CEO | MIXED | — | −$27.10K |
| 2025-03-12 | Lisa Delfini | Chief Financial Officer | A | +38,400 deriv. | — |
| 2025-03-12 | Thomas Sciascia | Chief Scientific Officer | A | +32,000 deriv. | — |
| 2025-03-12 | Jennifer L Good | President & CEO | A | +54,400 deriv. | — |
| 2025-03-12 | Christopher Galletta | See Remarks | A | +4,560 deriv. | — |
| 2025-03-12 | Farrell Simon | Chief Commercial Officer | MIXED | +31,250 | −$227.23K |
| 2025-02-20 | Christopher Galletta | See Remarks | A | +41,000 deriv. | — |
| 2025-02-20 | Jennifer L Good | President & CEO | A | +811,000 deriv. | — |
| 2025-02-20 | Lisa Delfini | Chief Financial Officer | A | +225,500 deriv. | — |
| 2025-02-20 | James V Cassella | Chief Development Officer | A | +257,500 deriv. | — |
| 2025-02-20 | Thomas Sciascia | Chief Scientific Officer | A | +116,000 deriv. | — |
| 2025-02-20 | Farrell Simon | Chief Commercial Officer | A | +225,500 deriv. | — |
| 2025-01-10 | Lisa Delfini | Chief Financial Officer | M | +6,000 | +$3.07K |
| 2024-12-17 | Christopher Galletta | See Remarks | M | +15,000 | +$7.67K |
| 2024-10-01 | James V Cassella | Chief Development Officer | A | +400,000 deriv. | — |
| 2024-09-09 | Jennifer L Good | President & CEO | MIXED | — | −$9.71K |
| 2024-09-05 | Jennifer L Good | President & CEO | MIXED | — | −$91.37K |
| 2024-08-29 | David P Meeker | Director | MIXED | — | −$6.84K |
| 2024-08-21 | Thomas Sciascia | Chief Scientific Officer | MIXED | — | −$25.29K |
| 2024-08-16 | Thomas Sciascia | Chief Scientific Officer | MIXED | — | −$42.18K |
| 2024-06-14 | David P Meeker | Director | A | +30,000 deriv. | — |
| 2024-06-14 | James V Cassella | Director | A | +30,000 deriv. | — |
| 2024-06-14 | Edward T Mathers | Director | A | +30,000 deriv. | — |
| 2024-06-14 | Dominick Colangelo | Director | A | +30,000 deriv. | — |
| 2024-06-14 | Michael Thomas Heffernan | Director | A | +30,000 deriv. | — |
| 2024-06-14 | Anne Vanlent | Director | A | +30,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Edward T Mathers | Director | 948,948 | $13.22M |
| David P Meeker | Director | 685,012 | $9.54M |
| Thomas Sciascia | Chief Scientific Officer | 221,373 | $3.08M |
| Jennifer L Good | President & CEO | 218,576 | $3.04M |
| Farrell Simon | Chief Commercial Officer | 158,213 | $2.20M |
| Lisa Delfini | Chief Financial Officer | 59,660 | $831.06K |
| Christopher Galletta | See Remarks | 26,095 | $363.50K |
| Anne Vanlent | Director | 20,983 | $292.29K |
| Michael Thomas Heffernan | Director | 6,351 | $88.47K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRVI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.